Molecular Remission Confirmed by Monitoring a PTPN11 Mutation in Myeloid Leukemia of Down Syndrome Treated With Reduced‐Intensity Stem Cell Transplantation: A Case Report
Year: 2025
Type: article
Study design: Case Report
Abstract: The authors declare the following potential conflicts of interest: Y.A. has received consulting fees from Quantdetect, Inc., honoraria from AbbVie and Chugai. S.S.N. receives honoraria from Thermo Fisher Scientific, MSD K.K., Finggal Link Co., Ltd., Nippon Kayaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Iwate Prefecture; research funding from Taiho Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan, LSI Medience Co., Ltd., Qiagen, and Roche Diagnostics; serves as CEO and is a shareholder of Quantdetect, Inc.; receives patent compensation (Patent #6544783, PCT/JP2022/43189) concerning the dPCR primer/probe library OTS-1000ex; and receives research support from Geninus, Array Jet, and Thermo Fisher Scientific. The other authors declare no conflicts of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Source: Pediatric Blood & Cancer
Authors: Taro Yoshida, Hideki Muramatsu, Shuta Ishikawa, Keisuke Oikawa, Yoshiko Asakura, Shoko Miura, Akiko Yashima‐Abo, Satoshi S. Nishizuka, Manabu Wakamatsu, Kiminori Terui, Tsutomu Toki, Etsuro Ito, Mikiya Endo, Manami Akasaka
Institutions: Iwate Medical University, Nagoya University, Hirosaki University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Hirosaki University
OpenAlex ID: W7117359078